Trametinib Shows Promise for Children with Relapsed or Refractory JMML
- OPACC
- Jun 17, 2024
- 1 min read
The MEK inhibitor trametinib (Mekinist) was an effective treatment for pediatric patients with relapsed or refractory juvenile myelomonocytic leukemia (JMML) enrolled in a phase II clinical trial, with seven of 10 patients alive after a median of two years, according to results published in Cancer Discovery, a journal of the American Association for Cancer Research (AACR).
Comments